Shares of Immunomedics, Inc. (NASDAQ:IMMU) have been assigned an average recommendation of “Buy” from the nine analysts that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $39.00.

A number of equities research analysts recently issued reports on IMMU shares. ValuEngine upgraded Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 2nd. BidaskClub upgraded Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, October 12th. Zacks Investment Research cut Immunomedics from a “hold” rating to a “sell” rating in a research note on Thursday, July 12th. Wells Fargo & Co boosted their price objective on Immunomedics from $31.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, B. Riley boosted their price objective on Immunomedics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, August 24th.

Institutional investors have recently made changes to their positions in the stock. RA Capital Management LLC bought a new stake in shares of Immunomedics during the second quarter valued at about $73,845,000. BlackRock Inc. increased its position in shares of Immunomedics by 24.3% during the second quarter. BlackRock Inc. now owns 11,228,828 shares of the biopharmaceutical company’s stock valued at $265,786,000 after buying an additional 2,195,066 shares during the period. American Century Companies Inc. bought a new stake in shares of Immunomedics during the second quarter valued at about $36,571,000. Voya Investment Management LLC increased its position in shares of Immunomedics by 2,844.1% during the second quarter. Voya Investment Management LLC now owns 1,333,820 shares of the biopharmaceutical company’s stock valued at $31,571,000 after buying an additional 1,288,515 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of Immunomedics by 66.4% during the second quarter. Janus Henderson Group PLC now owns 3,217,759 shares of the biopharmaceutical company’s stock valued at $76,164,000 after buying an additional 1,284,303 shares during the period. Institutional investors and hedge funds own 78.25% of the company’s stock.

Shares of NASDAQ:IMMU traded up $0.01 during midday trading on Thursday, reaching $22.36. The company had a trading volume of 73,841 shares, compared to its average volume of 2,145,444. The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.83 and a current ratio of 14.83. The company has a market capitalization of $3.89 billion, a P/E ratio of -21.64 and a beta of 1.85. Immunomedics has a 52-week low of $8.68 and a 52-week high of $27.33.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Thursday, August 23rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.46). The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $4.27 million. Immunomedics had a negative return on equity of 124.54% and a negative net margin of 12,701.21%. Immunomedics’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.48) earnings per share. As a group, research analysts predict that Immunomedics will post -1.09 earnings per share for the current year.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.